Am J Obstet Gynecol:宫颈癌的生存趋势

2015-11-30 candy 译 MedSci原创

目的:近30年宫颈癌的治疗取得了巨大的进展,对于人群水平的生存率是否得到改善,仍然不清楚。研究调查相对生存率,宫颈癌的生存率与不同时间对照比较。设计:研究1983年-2009年间记录在Surveillance、Epidemiology和End Results数据库,被诊断为宫颈癌的病人。生存模型由年龄、种族、分期、每年的诊断和诊断后的时间来调整。比较宫颈癌病人具体分期的相关生存变化和与总人口匹配的

目的:近30年宫颈癌的治疗取得了巨大的进展,但人群水平的生存率是否得到改善,仍然不清楚。研究调查相对生存率,宫颈癌的生存率与不同时间对照比较。

设计:研究1983年-2009年间记录在Surveillance、Epidemiology和End Results数据库,被诊断为宫颈癌的病人。生存模型由年龄、种族、分期、每年的诊断和诊断后的时间来调整。比较宫颈癌病人具体分期的相关生存变化和与总人口匹配的随着时间推移的年龄、种族和年份因素。

结果:共纳入46932例确诊病人。I期宫颈癌女性,2009年被确诊的病人的风险比相较2000年为0.91(95%置信区间0.86-0.95);与1990年比较:HR 0.81(95%CI,0.73-0.91);与1983年比较:HR 0.75(95%CI 0.64-0.88)。III期宫颈癌女性,2009年确诊的病人相对于2000年、1990年和1983年的风险比分别为:0.83 (95% CI, 0.80–0.87),0.68 (95% CI, 0.62–0.75), 0.59 (95% CI, 0.52–0.68)。同样的生存提高趋势表现在II期宫颈癌女性患者中。对于IV期宫颈癌患者则没有表现出随着时间推移相关生存率的提高,其数据无显著统计学意义。

结论:I-III期的宫颈癌患者的相对生存率随着时间提高,但对转移性病人的变化不大。

原始出处:


Wright, J. D., et al. (2015). Population-level trends in relative survival for cervical cancer.Am J Obstet Gynecol 213(5): 670 e671-677.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2043884, encodeId=d22f204388456, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sat Dec 26 04:02:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011220, encodeId=501020112208e, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Sun Nov 06 20:02:00 CST 2016, time=2016-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407959, encodeId=3588140e95989, content=<a href='/topic/show?id=92194628826' target=_blank style='color:#2F92EE;'>#宫颈#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46288, encryptionId=92194628826, topicName=宫颈)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11102737131, createdName=一闲, createdTime=Wed Dec 02 12:02:00 CST 2015, time=2015-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=44305, encodeId=28784430531, content=加油~宫颈癌, beContent=null, objectType=article, channel=null, level=null, likeNumber=5, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyhRUzmFEmHvdIaOns4DmF3BicVffXjkOjBTiaMUIA4o7feGvE5IJ0SfSco4ib955Rx7bvWlib7j9V15xp/0, createdBy=814d1631326, createdName=cmn, createdTime=Tue Dec 01 19:47:00 CST 2015, time=2015-12-01, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2043884, encodeId=d22f204388456, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sat Dec 26 04:02:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011220, encodeId=501020112208e, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Sun Nov 06 20:02:00 CST 2016, time=2016-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407959, encodeId=3588140e95989, content=<a href='/topic/show?id=92194628826' target=_blank style='color:#2F92EE;'>#宫颈#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46288, encryptionId=92194628826, topicName=宫颈)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11102737131, createdName=一闲, createdTime=Wed Dec 02 12:02:00 CST 2015, time=2015-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=44305, encodeId=28784430531, content=加油~宫颈癌, beContent=null, objectType=article, channel=null, level=null, likeNumber=5, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyhRUzmFEmHvdIaOns4DmF3BicVffXjkOjBTiaMUIA4o7feGvE5IJ0SfSco4ib955Rx7bvWlib7j9V15xp/0, createdBy=814d1631326, createdName=cmn, createdTime=Tue Dec 01 19:47:00 CST 2015, time=2015-12-01, status=1, ipAttribution=)]
    2016-11-06 yhy100200
  3. [GetPortalCommentsPageByObjectIdResponse(id=2043884, encodeId=d22f204388456, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sat Dec 26 04:02:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011220, encodeId=501020112208e, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Sun Nov 06 20:02:00 CST 2016, time=2016-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407959, encodeId=3588140e95989, content=<a href='/topic/show?id=92194628826' target=_blank style='color:#2F92EE;'>#宫颈#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46288, encryptionId=92194628826, topicName=宫颈)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11102737131, createdName=一闲, createdTime=Wed Dec 02 12:02:00 CST 2015, time=2015-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=44305, encodeId=28784430531, content=加油~宫颈癌, beContent=null, objectType=article, channel=null, level=null, likeNumber=5, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyhRUzmFEmHvdIaOns4DmF3BicVffXjkOjBTiaMUIA4o7feGvE5IJ0SfSco4ib955Rx7bvWlib7j9V15xp/0, createdBy=814d1631326, createdName=cmn, createdTime=Tue Dec 01 19:47:00 CST 2015, time=2015-12-01, status=1, ipAttribution=)]
    2015-12-02 一闲
  4. [GetPortalCommentsPageByObjectIdResponse(id=2043884, encodeId=d22f204388456, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sat Dec 26 04:02:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011220, encodeId=501020112208e, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Sun Nov 06 20:02:00 CST 2016, time=2016-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407959, encodeId=3588140e95989, content=<a href='/topic/show?id=92194628826' target=_blank style='color:#2F92EE;'>#宫颈#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46288, encryptionId=92194628826, topicName=宫颈)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11102737131, createdName=一闲, createdTime=Wed Dec 02 12:02:00 CST 2015, time=2015-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=44305, encodeId=28784430531, content=加油~宫颈癌, beContent=null, objectType=article, channel=null, level=null, likeNumber=5, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyhRUzmFEmHvdIaOns4DmF3BicVffXjkOjBTiaMUIA4o7feGvE5IJ0SfSco4ib955Rx7bvWlib7j9V15xp/0, createdBy=814d1631326, createdName=cmn, createdTime=Tue Dec 01 19:47:00 CST 2015, time=2015-12-01, status=1, ipAttribution=)]
    2015-12-01 cmn

    加油~宫颈癌

    0

相关资讯

里程碑!欧盟批准罗氏安维汀(Avastin)联合化疗治疗晚期宫颈癌

安维汀(Avastin)是瑞士制药巨头罗氏(Roche)第二畅销的抗癌药物,2014年全球销售额高达70.21亿美元,位列2014年全球最畅销的25个药物榜单第7名。在欧盟,Avastin已获批的适应症包括:乳腺癌、结直肠癌、非小细胞肺癌、卵巢癌。 近日,Avastin(bevacizumab,贝伐单抗)在欧盟监管方面再度传来喜讯,欧盟委员会(EC)已批准Avastin联合标准化疗(紫杉醇+

The Lancet Oncol:预防宫颈癌,打一针就行!

宫颈癌是全球最致命但也是最容易预防的女性癌症类型,人乳头瘤病毒(HPV)感染是罪魁祸首,导致了99%的宫颈癌病例,其中2种基因型(HPV-16/18)占到了70%。接种疫苗是预防宫颈癌的一种有效手段,当前宫颈癌疫苗的免疫程序通常为2针(0,6个月)或者3针(0,1,6个月)。然而令人担忧的现实情况是,有相当多的年轻女性并没有按规定及时地完成2针或3针注注射。这是否会降低疫苗预防HPV感染的效果呢?

Lancet Oncol:CP化疗中加入西地尼布,治疗宫颈癌可提高疗效 (CIRCCa研究)

对转移或复发宫颈癌患者进行传统标准的化疗,疗效很差,反应率仅为20-30%,并且整体生存率很难超过1年。肿瘤血管生成过多和瘤体内 VEGF 浓度过高是该疾病预后差的特征之一。西地尼布是一个对VEGFR1, 2, 3均有效的酪氨酸激酶抑制剂。研究者进行了一项试验,评估对转移或复发宫颈癌患者在卡铂+紫杉醇化疗基础上,添加西地尼布后效果如何。此项随机、双盲、安慰剂对照的2期试验在英国的17家医疗中心进行

欧洲药品管理局启动HPV疫苗安全性调查

近日,欧洲药品管理局(EMA)将针对广泛使用的两种预防宫颈癌的疫苗展开安全性调查。这次调查主要针对的HPV疫苗包括葛兰素史克的Cervarix和默沙东的Gardasil/Silgard(新版本Gardasil 9刚刚获批,这两种疫苗获批已经接近十年了。 欧洲药品管理局这次主要针对已经报道的两种副反应——复杂局部疼痛综合征(CRPS)以及体位性心动过速综合征(PoTS),他们试图调查清楚这两种副反

CA权威回顾--癌症可以药物预防吗?

可以预防的癌症 乳腺癌 宫颈癌 食道癌 预防

新HPV疫苗能预防80%宫颈癌

美国的一项新研究表明,在儿童十二岁之前给他们注射最新的人乳头瘤病毒(HPV)疫苗能有80%的概率预防宫颈癌。 研究表明,该疫苗(被称为9-Valent)能预防9中不同的人乳头瘤病毒株,同时也可能能预防19,000种其他癌症,包括肛门癌和阴茎癌。新的HPV疫苗相比前一代而言,其保护作用提升了11%。研究还发现,这种疫苗可以预防5.7%的咽喉癌,而咽喉癌则是常见癌症中第二个最与HPV相关的癌症。